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Summary 
We have previously shown that continuous administration of anti-interleukin 10 (anti-IL-10) 
antibodies (Abs) to BALB/c mice modifies endogenous levels of autoantibodies,  tumor necrosis 
factor ol (TNF-o0, and interferon % three immune mediators known to affect the development 
of autoimmunity in "lupus-prone"  New Zealand black/white (NZB/W)Ft mice. To explore the 
consequences of IL-10 neutralization  in NZB/W F1 mice, animals were injected two to three 
times per week from birth until 8-10 mo of age with anti-IL-10 Abs or with isotype control 
Abs. Anti-IL-10 treatment substantially delayed onset of autoimmunity in NZB/W F1 mice as 
monitored either by overall survival, or by development of proteinuria,  glomerulonephritis,  or 
autoantibodies. Survival at 9 mo was increased from 10 to 80% in anti-IL-10-treated mice relative 
to Ig isotype-treated controls. This protection against autoimmunity appeared to be due to an 
anti-IL-10-induced  upregulation of endogenous  TNF-oe,  since anti-IL-10-protected  NZB/W 
F1 mice rapidly developed autoimmunity when neutralizing anti-TNF-oe Abs were introduced 
at 30 wk along with the anti-IL-10 treatment. Consistent with the protective role of anti-IL-10 
treatment in these experiments, continuous administration  of IL-10 from 4 until 38 wk of age 
accelerated the onset of autoimmunity in NZB/W F, mice. The same period of continuous 
IL-10 administration did not appear to be toxic to, or cause development of  lupus-like autoimmunity 
in normal BALB/c  mice. These data suggest that IL-10 antagonists may be beneficial  in the treatment 
of human systemic lupus  erythematosus. 
T 
he (New Zealand black  x  New Zealand white [NZB  x 
NZW1])  F,  hybrid mouse develops a severe autoim- 
mune disease that closely resembles SLE in humans (1-3). 
NZB/W  F1  mice spontaneously  develop a fatal  immune 
complex-mediated glomerulonephritis around 6-9 mo in fe- 
male animals, and 12-18 mo in male animals. Previous at- 
tempts to define the underlying cause of autoimmunity in 
NZB/W  F1  mice have focused on  the  potential  role  of 
MHC genes. Indeed, IFN-y, a cytokine which upregulates 
expression of MHC class II antigens in a wide variety of cell 
types (4-6),  accelerates the development  of autoimmunity 
in NZB/W F, mice (7-10).  More recently, several studies 
(11-14) have suggested that the TNF-oe gene, which is lo- 
cated within the MHC complex (15-17), may be involved 
in the pathogenesis of lupus nephritis in NZB/W F1 mice. 
These studies reveal that NZB/W F, mice produce excep- 
tionally low levels of TNF-o~, and that this correlates with 
a restriction fragment length polymorphism in the TNF-o~ 
1 Abbreviation used in this paper: NZB/W, New Zealand  black/white. 
gene (11), and a polymorphism in simple dinudeotide tandem 
repeats in the 5' regulatory region of the TNF-ot gene (13, 
14). A causative role for these observations is implied by the 
fact  that  replacement  therapy with  recombinant TNF-ot 
significantly delays development of nephritis in NZB/W F1 
mice (11, 12). 
IL-10 is a cytokine produced by subsets of activated T cells, 
B cells, and macrophages which mediates a variety of both 
immunostimulatory and immunosuppressive  properties  in 
mouse and human in vitro assays (for a review see references 
18 and 19). In a recent effort to evaluate the physiological 
role of IL-10, we have treated BALB/c mice continuously 
from birth until 8 wk of age with neutralizing anti-IL-10 
Abs (20, 21). Consistent with the known in vitro properties 
of IL-10 (18, 19), anti-IL-10-treated  mice are characterized 
by elevated levels of endogenous IFN-3, and TNF-c~ (20, 21). 
The elevated IFN-3' in turn leads to the depletion of a nu- 
merically small subset of B lymphocytes, termed Lyl, CD5, 
or B-1 B cells (20), a population from which most murine 
autoantibodies are derived (22). These studies in normal mice 
suggested that neutralization of IL-10 may produce some de- 
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endogenous TNF-c~ and reduction of autoantibody produc- 
tion,  and  some undesirable  consequences,  i.e.,  elevation  of 
endogenous  IFN-3'.  In this  report,  we directly address the 
overall effects of continuous  anti-IL-10 treatment on devel- 
opment of autoimmunity in NZB/W  Ft female mice. Our 
data indicate that neutralization of IL-10 significantly delays 
onset of autoimmunity in these mice because of an upregula- 
tion  of endogenous  TNF-ot. 
Materials and Methods 
Mice.  NZB/W  F1 mice were bred in our colony at DNAX 
Research Institute using NZB females purchased from The Jackson 
Laboratory (Bar Harbor, ME) and NZW males purchased from 
Simonsen Laboratories (Gilroy,  CA).  Only female F1 mice were 
used in this study because of their more rapid onset of autoimmunity. 
Anti-IL,  IO Treatment.  Groups of 17-23 B/W  F1 female mice 
were treated with either a rat IgM (designated SXC.1) or a rat IgG1 
(designated JES 2A5) mAb specific for murine IL-10. Details about 
the production and characteristics of these Abs are given elsewhere 
(23,  24).  Similarly,  groups of 21-23 age-matched B/W F1 female 
mice were treated with either of two isotype-matched control mAbs, 
designated JS/D (IgM) or GLl13 (IgG1). Anti-IL-10 and isotype 
control mAbs were harvested as ascites from athymic nude (nu/nu) 
mice, purified by two sequential ammonium sulfate precipitation 
steps, dialyzed against PBS, and quantitated by protein electropho- 
resis and measurement of optical density. Treatment consisted of 
3 parts: during the first week after birth, 0.2 mg of mAb per mouse 
was injected intraperitoneally either four or two times per week 
for the IgM and IgG1 Abs, respectively.  During the second week, 
0.5  mg of mAb per mouse was injected intraperitoneally either 
three or two times per week for the IgM and IgG1 Abs respec- 
tively; and from 3 wk of age and onwards, I mg of mAb per mouse 
was injected intraperitoneally either three or two times per week 
for IgM and IgG1 Abs,  respectively. 
Assessment of Renal Disease.  Renal disease was assessed either 
via the development of proteinuria or by histological evaluation 
of glomerulonephritis. Proteinuria was measured colorimetrically 
using dip sticks (Albustix; Miles Laboratories, Inc., Elkhart, IN), 
and graded according to the following code: trace, 10 mg/dl; 1+, 
30 mg/dl; 2+, 100 mg/dl; 3+, 300 mg/dl; and 4+,  1,000 mg/dl. 
Severity of glomerulonephritis was evaluated histologically  by tissue 
sectioning and staining, and was graded on a 0-4+  scale based 
on the intensity and extent ofhistopathologic changes, as described 
previously by Berden et al. (25). Briefly, the score system for evalu- 
ating severity of glomerulonephritis was as follows:  a grade of 0 
was given to kidneys without glomerular lesions;  1+ lesions  cor- 
responded to minimal thickening of the mesangium; 2+  lesions 
contained noticeable increases  in both mesangial and glomerular 
cellularity; 3 +  lesions were characterized by the preceding condi- 
tions with superimposed inflammatory exudates and capsular adhe- 
sions;  and in 4+  lesions,  the glomerular architecture was obliter- 
ated  in  >70%  of glomeruli,  and  tubular  cast  formation  was 
extensive. 
Autoantibody ELISA.  Serum antibodies specific for double- or 
single-stranded DNA (ds or ssDNA) were quantitated by ELISA 
as described elsewhere (26).  Briefly, 5/~g/ml ds- or ss-DNA was 
used to coat ELISA plates (Flow Laboratories, McLean,  VA) in an 
overnight incubation at 4~  Antigen-coated plates were subse- 
quently blocked for 1 h with PBS containing 0.05%  Tween 20, 
0.02%  NAN3, and 0.1%  BSA,  then  incubated for 1 h  at room 
temperature with test or standard sera diluted from 1:100 in two- 
fold serial  dilutions.  Plates  were then washed with PBS-0.05% 
Tween 20, and incubated for I h with 1/~g/ml horseradish peroxi- 
dase (HRP)-conjugated anti-mouse IgG or IgM (Zymed Labora- 
tories, Inc., S. San Francisco, CA). Absorbance was measured using 
a microplate reader (Vmax; Molecular Devices,  Menlo Park, CA) 
30 min after the addition of 1 mg/ml 2,2'-Azinobis (3-ethylbenz- 
thiazoline-6-sulfonic Acid); ABTS (Sigma Chemical Co., St. Louis, 
MO). Anti-DNA titers were expressed as units, using a reference 
standard of pooled serum from 4-too-old MRL/MpJ-lpr/lpr mice 
provided by Dr. Shelby Umland (Schering-Plough Corp., Kenil- 
worth, NJ). A 1:100 dilution of this standard serum was arbitrarily 
assigned a value of 100 U/ml. 
Serum Concentration of TNF-c~.  Serum levels of TNF-ot were 
evaluated using a cytokine-specific ELISA, commercially available 
from Endogen,  Inc.  (Boston,  MA). 
Results 
Continuous Administration of Anti-IL-lO Antibodies Delays 
Onset  of Autoimmunity  in  NZB/W  FI  Mice.  In  normal 
mice, continuous administration of anti-IL-10 Abs from birth 
until adulthood alters the animals' levels of IFN-3', TNF-c~, 
and autoantibodies (20, 21), three mediators known to affect 
the development of autoimmunity in lupus-prone NZB/W 
F1 mice (3,  7-14).  To determine whether  IL-10 neutraliza- 
tion in NZB/W  F1 mice may indeed influence  their devel- 
opment of autoimmunity, groups of 20-23 female NZB/W 
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Figure  1.  Anti-IL-lO Ab treatment delays 
onset of autoimmunity in NZB/W F1 mice. 
(Expt. 1) Groups of 23 female mice were in- 
jected three times per week from birth and 
throughout the entire study with either SXC.1 
rat IgM anti-mouse Ibl0 Ab (e) or an iso- 
type control Ab designated  JS/D (O). Animal 
survival was monitored over the following 41 
wk. (Expts. 2 and 3) Groups of 20 female mice 
were injected twice per week from birth and 
throughout  the entire study with either JES 
2A5 rat IgG1 anti-mouse I1-,10 Ab (e) or an 
isotype control Ab designated GLl13 (O). An- 
imal survival  was monitored over the following 
35 wk. 
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Figure  2.  Developmept of proteinuria  in  NZB/W  F1  female mice 
treated with anti-Ibl0 Abs. Groups of 22 female mice were injected three 
times per week from birth and throughout the entire study with either 
SXC.1 anti-IL-10 Ab (O) or an isotype control Ab (O). Development of 
renal disease was assessed by measuring  proteinuria  using Albustix dip 
sticks from weeks 12-42. Data show proportion of mice with more than 
300 mg protein/dl in their urine.  Similar results  were obtained  in two 
additional  experiments. 
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Autoantibody production in anti-IL-10-treated  NZB/W F1 
mice. NZB/W F1 female mice were injected with SXC.1 anti-Ibl0 Ab 
(O)  or an  isotype  control  (O)  three  times  per  week  from birth  and 
throughout the entire study. Sera coUected at 5 or 6 me were evaluated 
for content of IgG Ab binding ds-DNA using an ELISA described in 
Materials and Methods. Each circle represents an individual mouse. Serum 
IgM anti-ds DNA Abs were also decreased in anti-Ibl0-treated NZB/W 
F1 mice (data not shown). 
F1 mice were injected three times per week from birth until 
40 wk of age with either SXC.1 rat IgM anti-mouse IL-10 
mAb, or equivalent amounts of an isotype control Ab desig- 
nated J5/D. Specific  details of  the Ab administration through- 
out this time period are given in Materials and Methods. As 
shown in Fig.  1, expt.  1, isotype control Ab-injected mice 
died between 25 and 38 wk of age. Their survival curve was 
in  fact  indistinguishable  from  that  of untreated control 
NZB/W F1 mice maintained in the same DNAX animal fa- 
cility (data not shown).  In contrast, NZB/W Ft mice in- 
jected continuously from birth with SXC.1 anti-IL-10 Abs 
showed a substantially enhanced survival curve over the 41- 
wk monitoring period (Fig. 1, expt. 1). Survival at 9 me was 
increased from 10 to 80% in anti-IL-10-treated  NZB/W F1 
mice relative to isotype  control-treated NZB/W F1  mice 
(Fig. 1, expt. I). Similar results were obtained in two addi- 
tional experiments of this nature, each using similar numbers 
of NZB/W F1 mice per group,  although monitoring the 
animals for slightly shorter time periods (Fig. 1, expts. 2 and 
3).  In experiments  2 and 3, animals were treated continu- 
ously from birth with either JES 2A5 rat IgG1 antimurine 
IL-10 Ab, or the isotype control GLl13 Ab. Thus, this second 
anti-IL-10 Ab also prolonged the survival of NZB/W FI 
mice. 
The survival curves shown in Fig. I presumably reflected 
death due to development of autoimmunity, suggesting that 
neutralization  of IL-IO delayed development of autoimmu- 
nity in NZB/W FI mice. This assumption was validated by 
the fact that the protective effect of anti-IL-10 treatment of 
NZB/W Ft mice was evident  at the level of development 
of proteinuria (Fig. 2), serum autoantibody levels (Fig. 3), 
and glomerulonephritis (Figs. 4 and 5).  By each of these 
criteria,  continuous treatment of NZB/W  F~  mice from 
birth through 35-42 wk with anti-IL-10 Abs substantially 
delayed  the onset of autoimmunity  in these animals. The results 
shown in Figs. 2 -5 were reproduced in three individual ex- 
periments, two of which used a second antimurine IL-10 Ab, 
designated JES 2A5,  and its isotype control (GLl13). 
IL-IO  Neutralization Delays Onset of Autoimmunity  in 
NZB/W FI Mice because of Elevation of TNF-o~.  Several 
studies have implicated atypically low endogenous TNF-oL 
levels as a contributing factor in the pathogenesis of autoim- 
munity in NZB/W Ft mice (11-14). Since IL-10 neutraliza- 
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Figure  4.  Histological evaluation of severity of renal disease in control 
and  treated  NZB/W  F1 mice.  Kidneys were collected,  sectioned,  and 
stained by standard procedures. Severity of glomerulonephritis was graded 
according to the following score system: a grade of 0 was given to kidneys 
without glomerular lesions; 1+  lesions correspond to minimal thickening 
of the mesangium; 2+ lesions contained noticeable increases in both mesan- 
gial  and  glomerular cellularity;  3+  lesions  were characterized  by the 
preceding conditions  with superimposed inflammatory exudates and cap- 
sular adhesions; and in 4+  lesions, the glomerular architecture  was oblit- 
erated in >70% of glomeruli, and tubular cast formation was extensive. 
Resuhs show number of animals in each group with a particular  grading 
of renal disease, with each circle representing  an individual  mouse. 
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Figure  6.  Serum  TNF-r  levels 
in anti-lL-10-treated NZB/W F1 
mice. NZB/W female mice were 
N  injected  with SXC.1 anti-IL-10  Ab 
￿9  ￿9  (0)  or  an  isotype control  (O) 
three times per week from birth 
￿9  and throughout  the entire study. 
Sera collected  at 5, 7, or 8 mo were 
￿9  evaluated  for  TNF-ot  content 
8o0  using a cytokine-specific  ELISA. 
8'  Each circle  represents  an individual 
mouse. 
Figure  5.  Histological examination of kidneys from anti-IL-10-treated 
NZB/W F1 mice (PAS staining; H250). (A) A typical grade 4 lesion ob- 
served in the isotype control-treated  mice shown in Fig. 4, Note accumu- 
lation of amorphous PAS-positive  materials in the mesangial matrix, and 
protein  casts in  renal tubules. (B)  A  grade  1 lesion in  the  anti-IL-10 
Ab-treated group of mice. Note slight thickening of the mesangium. 
tion in normal mice is accompanied by an increase in serum 
TNF-c~ levels (21), we considered whether the above protec- 
tive  effects  of  anti-IL-10  treatment  of  NZB/W  F1  mice 
could be explained by elevation of this cytokine. Indeed, treat- 
ment  of NZB/W  F1  mice  from  birth  until  8  mo  of age 
caused a marked increase in serum TNF-ot levels as compared 
with  isotype-treated  controls  (Fig.  6).  When  NZB/W  F1 
mice that had been treated from birth  with  anti-IL-10 Abs 
additionally  received injections  of neutralizing  anti-TNF-ot 
mAbs at weeks 30-35 of the experiment, the animals rapidly 
developed autoimmunity as indicated by a striking reduction 
in their survival (Fig.  7), as well as the development of both 
proteinuria  (data not  shown)  and  glomerulonephritis  (Fig. 
4).  These  data  strongly  suggest  that  the  anti-IL-10-medi- 
ated delay in onset of autoimmunity  in NZB/W  F1 mice is 
due  to  an  elevation  of endogenous  TNF-ot  levels  in  these 
animals. 
IL-IO Administration Accelerates the Onset of Autoimmunity 
in NZB/W F1 Mice.  The experiments described above sug- 
gest  that  IL-10  neutralization  in  NZB/W  F1  mice  delays 
onset  of autoimmunity  in  these  animals by elevating  their 
endogenous levels of TNF-c~. This condusion was supported 
by separate experiments which  showed that continuous  ad- 
ministration  of IL-10 to NZB/W  F1 mice caused a small but 
significant acceleration of onset of autoimmunity. Groups of 
20 female NZB/W  F:  mice were injected  intraperitoneally 
three  times  per  week  from 4  to  35  wk  of age with  either 
1/~g recombinant murine IL-10 or an equivalent volume of 
PBS. As shown in Fig. 8, expt. 1, PBS injected animals showed 
a typical survival curve,  generally dying between 25 and 40 
weeks.  In IL-10 treated  animals,  the survival curve showed 
a more rapid onset of autoimmunity,  with death occurring 
on average 5 to 6 weeks earlier (Fig. 8, expt. 1). Similar results 
were obtained in a second independent experiment involving 
identical numbers of animals monitored for a slightly shorter 
period of time (Fig. 8, exlot. 2). The accelerated death of IL- 
10-treated NZB/W  F1 mice was accompanied by accelerated 
development of proteinuria and glomerulonephritis  (data not 
shown),  indicating  that  the  survival curves reflected death 
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Figure  7.  Anti-TNF-ot  Abs reverse anti-IL-10-mediated  protection of 
NZB/W  F1  mice. Groups  of 36  and  18  NZB/W  female mice were 
injected twice a week with 2A5 anti-IL-10  Ab (0, A) or an isotype con- 
trol Ab designated GLl13 (O), respectively,  from birth and throughout 
the entire experiment. Half of the animals injected with anti-IL-10 Ab 
additionally received XT22 anti-TNF Ab twice a week commencing at 
30 wk after birth (A). Animal survival  was monitored over a 34-wk period. 
Similar results were obtained in two additional experiments. 
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Figure 8,  Ibl0  administration 
accelerates onset of autoimmunity 
in NZB/W F1 mice. Groups of 20 
female NZB/W F1 mice were in- 
jected three times per week from 4 
wk of age and throughout the en- 
tire experiment with either 1 #g i.p. 
murine IL-10 (O) or an equivalent 
volume ofPBS i.p.  (e). The effect 
of identical treatment of groups of 
20 BALB/c mice are shown for com- 
parison (~,m). 
due to autoimmunity. Administration of equivalent amounts 
of IL-10 to normal BALB/c mice from 4  to 38-42 wk of 
age did not induce autoimmune disease in these animals, as 
evaluated by animal survival (Fig. 8) or development of pro- 
teinuria (data not shown). 
Discussion 
We show here that continuous treatment of lupus-prone 
NZB/W  F1 mice from birth until 38-42  wk of age with 
anti-ILol0 Abs substantially delays onset of autoimmunity 
in these animals. Conversely, continuous administration of 
IL-IO to NZB/W F1 mice from 4  to 38 wk of age causes 
a significant acceleration in the development of autoimmu- 
nity in these animals, while having no overt consequence in 
normal BALB/c mice. The protective effect of anti-IL-10 Ab 
administration to NZB/W F1 mice can be explained by the 
elevation of endogenous TNF-ot levels that results from this 
treatment (21 and Fig. 6). This conclusion can be drawn from 
the fact that neutralizing anti-TNF-ot Abs reversed the pro- 
tective effect of anti-IL-10 treatment when introduced into 
the anti-IL-10-treated animals some 30 wk after experiment 
initiation (Fig.  7). These data predict a potential clinical use 
for IL-10 antagonists in treatment of human SLE. Such treat- 
ment may be particularly relevant to the subset of SLE patients 
expressing  DR2 +  DQwl +  histocompatibility  antigens, 
since PBL from these patients produce atypically low levels 
of TNF-cr (27).  Conversely, the use of chronic long-term 
IL-10 administration may be contraindicated in SLE patients. 
On this point, it should be noted however that single-dose 
or short-term IL-10 administration had no significant effect 
on NZB/W  F1 mice (our unpublished observations),  and 
long-term IL-10 administration had no significant effect on 
normal BALB/c mice (Fig.  8). 
The  mechanism  of  anti-IL-10-mediated  protection  of 
NZB/W  F1 mice from onset of autoimmunity suggests a 
protective role for TNF-ot in this disease. Indeed this has al- 
ready been demonstrated experimentally by direct cytokine 
administration (11, 12).  While the basis  of TNF-ot-medi- 
ated protection has not yet been elucidated, several known 
properties of this cytokine suggest potential mechanisms of 
action in this disease model. One possible explanation relates 
to the fact that TNF-ot significantly decreases IFN-3,-induced 
upregulation of MHC class II expression on different mature 
cells collected from NZB/W F1 mice (14, 28). Aberrant up- 
regulation of class II antigen expression is thought to be a 
causative mechanism in a variety of endocrine autoimmune 
diseases (29). Thus, suppression of this effect may be advan- 
tageous in NZB/W F1 mice. Alternatively, whereas TNF-ot 
does not suppress humoral immunity in normal or lupus mice 
(14,  30),  there have been some reports that long-term ad- 
ministration  of this  cytokine causes  suppression  of cell- 
mediated immunity in these animals (30).  The level of pro- 
tection afforded by IL-10 neutralization in NZB/W F1 mice 
is comparable to that previously obtained with direct adminis- 
tration of TNF-ot (11, 12).  The possibility of using either 
approach for treatment of SLE patients depends of course 
on translation of the current findings to the human disease 
situation,  and the long-term toxicity of these reagents. 
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